Immunocore

KIMMTRAK

  1. Home
  2.  / 
  3. J Code
  4.  / KIMMTRAK – J9274

Manufacturer:

Immunocore

Name:

KIMMTRAK

HCPCS Code Descriptor:

Injection, tebentafusp-tebn, 1 microgram

Category:

J Code

HCPCS:

J9274

NDC(s):

80446-0401-01

Primary Type:

Oncology

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

KIMMTRAK is an Oncology drug manufactured by Immunocore and administered via the Intravenous route of administration. The J Code: J9274 is aligned to the drug KIMMTRAK.

Kimmtrak is a type of monoclonal antibody and is used to treat certain types of cancer. Kimmtrak works by slowing down preventing the growth of cancer cells. Kimmtrak is administered via a 15-to-20-minute intravenous infusion. Kimmtrak is a branded drug manufactured by Immunocore Commercial. From July 2022 to September 2022, Kimmtrak was assigned to the temporary C Code: C9095. Beginning in October 2022, Kimmtrak received the J Code: J9274. Patient assistance programs for this medication can be found through Immunocore.

Access Pricing and More By Registering

HCPCS Added Date:

10/1/22

HCPCS Effective Date:

10/1/22

HCPCS Short Description:

Inj, tebentafusp-tebn, 1 mcg

Billing and Coding Guide:

https://www.kimmtrakhcp.com/KIMMTRAK-billing-and-coding-guide.pdf

Patient Assistance:

https://www.kimmtrakconnect.com/financial-assistance/

KIMMTRAK - J9274